Suven Pharmaceuticals Share Price
Sector: Biotechnology & Drugs
1154.00 +10.75 (0.94%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1132.00
Today’s High
1163.25
52 Week Low
597.00
52 Week High
1359.00
1148.70 +5.50 (0.48%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1133.20
Today’s High
1163.90
52 Week Low
598.00
52 Week High
1360.00
Key Metrics
- Market Cap (In Cr) 29495.48
- Beta 1.19
- Div. Yield (%) 0
- P/B 14.19
- TTM P/E 103.75
- Peg Ratio -17.24
- Sector P/E 26.62
- Open Price 1143.7
- Prev Close 1143.25
Suven Pharmaceuticals Analysis
Price Analysis
-
1 Week-2.13%
-
3 Months13.84%
-
6 Month-8.54%
-
YTD0.39%
-
1 Year76.75%
Risk Meter
- 41% Low risk
- 41% Moderate risk
- 41% Balanced Risk
- 41% High risk
- 41% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 3
- 3
- 3
- 1
- Buy
- 3
- 2
- 1
- 0.00
- Hold
- 0.00
- 0.00
- 0.00
- 0.00
- Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Strong Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Total
- 6
- 5
- 4
- 1
Suven Pharmaceuticals News
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy
1 min read . 03 Mar 2025Stocks to Watch: Suven Pharma, Reliance Power, Laurus Labs, Paytm, and more
3 min read . 09 Dec 2024Stock market today: Experts recommend four stocks to buy or sell on Tuesday
5 min read . 22 Oct 2024Suven Pharmaceuticals Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 1051.35
- Selling/ General/ Admin Expenses Total
- 159.66
- Depreciation/ Amortization
- 54.5
- Other Operating Expenses Total
- 50
- Total Operating Expense
- 700
- Operating Income
- 351.35
- Net Income Before Taxes
- 405.67
- Net Income
- 300.28
- Diluted Normalized EPS
- 11.89
- Period
- 2024
- Total Assets
- 2254.09
- Total Liabilities
- 203.42
- Total Equity
- 2050.66
- Tangible Book Valueper Share Common Eq
- 78.12
- Period
- 2024
- Cashfrom Operating Activities
- 358.48
- Cashfrom Investing Activities
- -362.25
- Cashfrom Financing Activities
- -13.8
- Net Changein Cash
- -17.57
- Period
- 2023
- Total Revenue
- 1340.33
- Selling/ General/ Admin Expenses Total
- 134.95
- Depreciation/ Amortization
- 47.73
- Other Operating Expenses Total
- 61.91
- Total Operating Expense
- 821.52
- Operating Income
- 518.81
- Net Income Before Taxes
- 559.73
- Net Income
- 411.29
- Diluted Normalized EPS
- 16.16
- Period
- 2023
- Total Assets
- 1965.74
- Total Liabilities
- 230.56
- Total Equity
- 1735.18
- Tangible Book Valueper Share Common Eq
- 65.72
- Period
- 2023
- Cashfrom Operating Activities
- 457.2
- Cashfrom Investing Activities
- -195.01
- Cashfrom Financing Activities
- -241.95
- Net Changein Cash
- 20.24
- Period
- 2022
- Total Revenue
- 1320.22
- Selling/ General/ Admin Expenses Total
- 128.12
- Depreciation/ Amortization
- 39.1
- Other Operating Expenses Total
- 51.84
- Total Operating Expense
- 779.69
- Operating Income
- 540.53
- Net Income Before Taxes
- 667.59
- Net Income
- 453.8
- Diluted Normalized EPS
- 17.83
- Period
- 2022
- Total Assets
- 1829.59
- Total Liabilities
- 302.41
- Total Equity
- 1527.18
- Tangible Book Valueper Share Common Eq
- 59.9
- Period
- 2022
- Cashfrom Operating Activities
- 330
- Cashfrom Investing Activities
- -136.21
- Cashfrom Financing Activities
- -156.41
- Net Changein Cash
- 37.38
- Period
- 2021
- Total Revenue
- 1009.72
- Selling/ General/ Admin Expenses Total
- 102.81
- Depreciation/ Amortization
- 31.64
- Other Operating Expenses Total
- 40.03
- Total Operating Expense
- 600.87
- Operating Income
- 408.84
- Net Income Before Taxes
- 467.67
- Net Income
- 362.34
- Diluted Normalized EPS
- 14.23
- Period
- 2021
- Total Assets
- 1474.47
- Total Liabilities
- 293.66
- Total Equity
- 1180.81
- Tangible Book Valueper Share Common Eq
- 46.28
- Period
- 2021
- Cashfrom Operating Activities
- 382.55
- Cashfrom Investing Activities
- -311.4
- Cashfrom Financing Activities
- -75.66
- Net Changein Cash
- -4.51
- Period
- 2020
- Total Revenue
- 833.79
- Selling/ General/ Admin Expenses Total
- 101.55
- Depreciation/ Amortization
- 23.86
- Other Operating Expenses Total
- 27.43
- Total Operating Expense
- 472.52
- Operating Income
- 361.27
- Net Income Before Taxes
- 404.51
- Net Income
- 317
- Diluted Normalized EPS
- 12.45
- Period
- 2020
- Total Assets
- 1172.81
- Total Liabilities
- 328.05
- Total Equity
- 844.76
- Tangible Book Valueper Share Common Eq
- 33.07
- Period
- 2020
- Cashfrom Operating Activities
- 415.95
- Cashfrom Investing Activities
- -421.53
- Cashfrom Financing Activities
- 6.37
- Net Changein Cash
- 0.79
- Period
- 2019
- Total Revenue
- 377.83
- Selling/ General/ Admin Expenses Total
- 47.75
- Depreciation/ Amortization
- 11.5
- Other Operating Expenses Total
- 13.15
- Total Operating Expense
- 215.09
- Operating Income
- 162.74
- Net Income Before Taxes
- 157.87
- Net Income
- 109.27
- Diluted Normalized EPS
- 4.29
- Period
- 2019
- Total Assets
- 783.02
- Total Liabilities
- 192.73
- Total Equity
- 590.29
- Tangible Book Valueper Share Common Eq
- 23.08
- Period
- 2019
- Cashfrom Operating Activities
- 50.4
- Cashfrom Investing Activities
- -65.48
- Cashfrom Financing Activities
- 25.98
- Net Changein Cash
- 10.9
- Period
- 2024-12-31
- Total Revenue
- 307.15
- Selling/ General/ Admin Expenses Total
- 63.29
- Depreciation/ Amortization
- 20.35
- Other Operating Expenses Total
- 70.53
- Total Operating Expense
- 209.8
- Operating Income
- 97.35
- Net Income Before Taxes
- 109.73
- Net Income
- 82.88
- Diluted Normalized EPS
- 3.23
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 257.72
- Selling/ General/ Admin Expenses Total
- 51.87
- Depreciation/ Amortization
- 16.96
- Other Operating Expenses Total
- 49.78
- Total Operating Expense
- 170.67
- Operating Income
- 87.05
- Net Income Before Taxes
- 99.5
- Net Income
- 82.21
- Diluted Normalized EPS
- 3.21
- Period
- 2024-09-30
- Total Assets
- 2505.56
- Total Liabilities
- 527.22
- Total Equity
- 1978.34
- Tangible Book Valueper Share Common Eq
- 67.05
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 177.67
- Cashfrom Investing Activities
- -142.29
- Cashfrom Financing Activities
- -45.79
- Net Changein Cash
- -10.41
- Period
- 2024-06-30
- Total Revenue
- 230.69
- Selling/ General/ Admin Expenses Total
- 45.62
- Depreciation/ Amortization
- 13.4
- Other Operating Expenses Total
- 14.46
- Total Operating Expense
- 164.16
- Operating Income
- 66.53
- Net Income Before Taxes
- 83.09
- Net Income
- 60.77
- Diluted Normalized EPS
- 2.39
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 252.93
- Selling/ General/ Admin Expenses Total
- 45.77
- Depreciation/ Amortization
- 17.41
- Other Operating Expenses Total
- 5.12
- Total Operating Expense
- 194.46
- Operating Income
- 58.47
- Net Income Before Taxes
- 70.85
- Net Income
- 53.37
- Diluted Normalized EPS
- 2.2
- Period
- 2024-03-31
- Total Assets
- 2254.09
- Total Liabilities
- 203.42
- Total Equity
- 2050.66
- Tangible Book Valueper Share Common Eq
- 78.12
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 358.48
- Cashfrom Investing Activities
- -362.25
- Cashfrom Financing Activities
- -13.8
- Net Changein Cash
- -17.57
- Period
- 2023-12-31
- Total Revenue
- 219.82
- Selling/ General/ Admin Expenses Total
- 32.83
- Depreciation/ Amortization
- 12.75
- Other Operating Expenses Total
- 14.42
- Total Operating Expense
- 167.43
- Operating Income
- 52.39
- Net Income Before Taxes
- 65.47
- Net Income
- 46.75
- Diluted Normalized EPS
- 1.84
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 231.05
- Selling/ General/ Admin Expenses Total
- 28.58
- Depreciation/ Amortization
- 11.89
- Other Operating Expenses Total
- 13.16
- Total Operating Expense
- 144.98
- Operating Income
- 86.07
- Net Income Before Taxes
- 105.41
- Net Income
- 79.56
- Diluted Normalized EPS
- 3.13
- Period
- 2023-09-30
- Total Assets
- 2119.77
- Total Liabilities
- 184.37
- Total Equity
- 1935.4
- Tangible Book Valueper Share Common Eq
- 73.59
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 252.31
- Cashfrom Investing Activities
- -237.89
- Cashfrom Financing Activities
- -21.64
- Net Changein Cash
- -7.23
- Period
- 2023-06-30
- Total Revenue
- 347.55
- Selling/ General/ Admin Expenses Total
- 28.74
- Depreciation/ Amortization
- 12.54
- Other Operating Expenses Total
- 16.21
- Total Operating Expense
- 193.13
- Operating Income
- 154.42
- Net Income Before Taxes
- 163.94
- Net Income
- 120.59
- Diluted Normalized EPS
- 4.74
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 369.36
- Selling/ General/ Admin Expenses Total
- 25.6
- Depreciation/ Amortization
- 11.96
- Other Operating Expenses Total
- 15.77
- Total Operating Expense
- 212.24
- Operating Income
- 157.12
- Net Income Before Taxes
- 166.21
- Net Income
- 123.97
- Diluted Normalized EPS
- 4.87
- Period
- 2023-03-31
- Total Assets
- 1965.74
- Total Liabilities
- 230.56
- Total Equity
- 1735.18
- Tangible Book Valueper Share Common Eq
- 65.72
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 450.91
- Cashfrom Investing Activities
- -194.84
- Cashfrom Financing Activities
- -235.83
- Net Changein Cash
- 20.24
- Period
- 2022-12-31
- Total Revenue
- 353.77
- Selling/ General/ Admin Expenses Total
- 29.68
- Depreciation/ Amortization
- 12.24
- Other Operating Expenses Total
- 18.13
- Total Operating Expense
- 219.32
- Operating Income
- 134.46
- Net Income Before Taxes
- 146.08
- Net Income
- 107.72
- Diluted Normalized EPS
- 4.23
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Suven Pharmaceuticals Technical
Moving Average
SMA
- 5 Day1198.52
- 10 Day1174.32
- 20 Day1139.56
- 50 Day1148.64
- 100 Day1148.85
- 300 Day1126.85
Suven Pharmaceuticals Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Laurus Labs
- 626.45
- 1.05
- 0.17
- 660.9
- 386.85
- 33781.47
- Ajanta Pharma
- 2781.9
- 104.7
- 3.91
- 3485.75
- 2022.05
- 34749.3
- Suven Pharmaceuticals
- 1154
- 10.75
- 0.94
- 1359
- 597
- 29495.48
- Piramal Pharma
- 214.95
- -1.05
- -0.49
- 307.85
- 135.85
- 28431.14
- Syngene International
- 616.85
- -12.8
- -2.03
- 960
- 608
- 24830.49
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Laurus Labs
- 94.22
- 7.54
- 18.12
- 11.88
- Ajanta Pharma
- 41.19
- 9.45
- 21.37
- 19.31
- Suven Pharmaceuticals
- 96.12
- 14.19
- 27.91
- 33.21
- Piramal Pharma
- 470.1
- 3.62
- -
- -
- Syngene International
- 53.66
- 5.35
- 13.02
- 15.03
Suven Pharmaceuticals Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 28-May-25
- Audited Results
- 12-Feb-25
- Quarterly Results
- 12-Nov-24
- Quarterly Results
- 09-Aug-24
- Quarterly Results
- 30-May-24
- Audited Results
- 05-Feb-24
- Quarterly Results
- 09-Nov-23
- Quarterly Results
- 08-Aug-23
- Quarterly Results
- 25-May-23
- Audited Results
- 06-Feb-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 19-Dec-24
- 21-Nov-24
- POM
- 28-Nov-24
- 28-Oct-24
- COM
- 09-Aug-24
- 15-Jul-24
- AGM
- 15-Feb-24
- 12-Jan-24
- POM
- 15-Dec-23
- 10-Nov-23
- AGM
- 14-Dec-23
- 13-Nov-23
- POM
- 18-Aug-22
- 09-May-22
- AGM
- 31-Aug-21
- 08-Jun-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 29-Aug-22
- 12-Sept-22
- 09-Sept-22
- 1
- 30-Aug-22
- 12-Sept-22
- 09-Sept-22
- 5
- 02-May-22
- 17-May-22
- 13-May-22
- 1
- 03-May-22
- 17-May-22
- 13-May-22
- 1
- 02-Feb-22
- 16-Feb-22
- 15-Feb-22
- 2
- 01-Feb-22
- 16-Feb-22
- 15-Feb-22
- 1
- 08-Jun-21
- 17-Aug-21
- 13-Aug-21
- 1
- 03-Feb-21
- 18-Feb-21
- 17-Feb-21
- 1


